A historical and practical review of first trimester aneuploidy screening

Seminars in Fetal and Neonatal Medicine

Volumn 19, Issue 3, 2014, Pages 183-187

  Russo, Melissa L ^a   Blakemore, Karin J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploidy; First trimester screening; Free human chorionic gonadotropin; Maternal serum screening tests; Nuchal translucency measurement; Pregnancy associated plasma protein A

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; COMPARATIVE STUDY; FIRST TRIMESTER PREGNANCY; HIGH RISK PATIENT; HUMAN; MATERNAL AGE; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT IDENTIFICATION; PRENATAL SCREENING; REVIEW; TWIN PREGNANCY; ADULT; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; HISTORY; PREGNANCY; PRENATAL DIAGNOSIS;

ADULT; ANEUPLOIDY; DOWN SYNDROME; FEMALE; HISTORY, 20TH CENTURY; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; ULTRASONOGRAPHY, PRENATAL;

EID: 84901604734     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2013.11.013     Document Type: Review

References (47)

1. Penrose L.S. The Colchester Survey: a clinical and genetic study of 1280 cases of mental defect 1938, HMSO/Privy Council of Medical Research Council, London.
2. Merkatz I.R., Nitowsky H.M., Macri J.N., Johnson W.E. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984, 148:886-894.
3. Cuckle H.S., Wald N.J., Lindenbaum R.H. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984, 323:926-929.
4. Macri J.N., Kasturi R.V., Krantz D.A., Cook E.J., Moore N.D., Young J.A., et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990, 163(4 Pt 1):1248-1253.
5. Canick J.A., Knight G.J., Palomaki G.E., Haddow J.E., Cuckle H.S., Wald N.J. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988, 95:330-333.
6. Van Lith J.M., Pratt J.J., Beekhuis J.R., Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992, 12:801-806.
7. Wald N.J., Cuckle H.S., Densem J.W., Nanchahal K., Royston P., Chard T., et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988, 297:883-887.
8. Haddow J.E., Palomaki G.E., Knight G.J., Foster D.L., Neveux L.M. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998, 5:115-119.
9. McGowan K.D., Blakemore K.J. Amniocentesis and chorionic villus sampling. Curr Opin Obstet Gynecol 1991, 3:221-229.
10. Spencer K., Macri J.N., Aitken D.A., Connor J.M. Free beta-hCG as first-trimester marker for fetal trisomy. Lancet 1992, 339:1480.
11. Bogart M.H., Pandian M.R., Jones O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987, 7:623-630.
12. Macri J.N., Spencer K., Aitken D., Garver K., Buchanan P.D., Muller F., et al. First-trimester free beta (hCG) screening for Down syndrome. Prenat Diagn 1993, 13:557-562.
13. Brambati B., Lanzani A., Tului L. Ultrasound and biochemical assessment of first trimester of pregnancy. The embryo: normal and abnormal development and growth 1990, 181-194. Springer-Verlag, London.
14. Wald N., Stone R., Cuckle H.S., Grudzinskas J.G., Barkai G., Brambati B., et al. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. BMJ 1992, 305:28.
15. Muller F., Cuckle H., Teisner B., Grudzinskas J.G. Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy. Prenat Diagn 1993, 13:633-636.
16. Down J.L. Observations on an ethnic classification of idiots. Clinical Lecture Reports, London Hospital 1866, 3:259-262.
17. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992, 304:867-869.
18. Brambati B., Cislaghi C., Tului L., Alberti E., Amidani M., Colombo U., et al. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling. Ultrasound Obstet Gynecol 1995, 5:9-14.
19. Pandya P.P., Kondylios A., Hilbert L., Snijders R.J., Nicolaides K.H. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995, 5:15-19.
20. Pandya P.P., Snijders R.J., Johnson S.P., De Lourdes Brizot M., Nicolaides K.H. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995, 102:957-962.
21. Snijders R.J., Noble P., Sebire N., Souka A., Nicolaides K.H. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998, 352:343-346.
22. Whitlow B.J., Chatzipapas I.K., Economides D.L. The effect of fetal neck position on nuchal translucency measurement. Br J Obstet Gynaecol 1998, 105:872-876.
23. Brambati B., Tului L., Bonacchi I., Shrimanker K., Suzuki Y., Grudzinskas J.G. Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 1994, 14:1043-1047.
24. Noble P.L., Abraha H.D., Snijders R.J., Sherwood R., Nicolaides K.H. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 1995, 6:390-395.
25. Orlandi F., Damiani G., Hallahan T.W., Krantz D.A., Macri J.N. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997, 10:381-386.
26. Spencer K., Souter V., Tul N., Snijders R., Nicolaides K.H. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999, 13:231-237.
27. Krantz D.A., Hallahan T.W., Orlandi F., Buchanan P., Larsen J.W., Macri J.N. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000, 96:207-213.
28. Wapner R., Thom E., Simpson J.L., Pergament E., Silver R., Filkins K., et al. First-trimester screening for trisomies 21 and 18. N Engl Med J 2003, 349:1405-1413. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group.
29. Wald N.J., Hackshaw A.K. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997, 17:821-829.
30. Dunstan F.D., Nix A.B. Screening for Down's syndrome: the effect of test date on the detection rate. Ann Clin Biochem 1998, 35(Pt 1):57-61.
31. Wald N.J., Watt H.C., Hackshaw A.K. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl Med J 1999, 341:461-467.
32. Wald N.J., Rodeck C., Hackshaw A.K., Walters J., Chitty L., Mackinson A.M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003, 10:56-104.
33. Malone F.D., Canick J.A., Ball R.H., Nyberg D.A., Comstock C.H., Bukowski R., et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl Med J 2005, 353:2001-2011.
34. Kleihauer E., Braun H., Betke K. Demonstration of fetal hemoglobin in erythrocytes of a blood smear (German). Klin Wochenschr 1957, 35:637-638.
35. Herzenberg L.A., Bianchi D.W., Schröder J., Cann H.M., Iverson G.M. Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-activated cell sorting. Proc Natl Acad Sci USA 1997, 76:1453-1455.
36. Iverson G.M., Bianchi D.W., Cann H.M., Herzenberg L.A. Detection and isolation of fetal cells from maternal blood using the fluorescence-activated cell sorter (FACS). Prenat Diagn 1981, 1:61-73.
37. Price J.O., Elias S., Wachtel S.S., Klinger K., Dockter M., Tharapel A., et al. Prenatal diagnosis with fetal cells isolated from maternal blood by multiparameter flow cytometry. Am J Obstet Gynecol 1991, 165(6 Pt 1):1731-1737.
38. Bianchi D.W., Simpson J.L., Jackson L.G., Elias S., Holzgreve W., Evans M.I., et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat Diagn 2002, 22:609-615.
39. Lo Y.M., Corbetta N., Chamberlain P.F., Rai V., Sargent I.L., Redman C.W., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
40. Fan H.C., Blumenfeld Y.J., Chitkara U., Hudgins L., Quake S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008, 105:16266-16271.
41. Chiu R.W., Chan K.C., Gao Y., Lau V.Y., Zheng W., Leung T.Y., et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008, 105:20458-20463.
42. Chiu R.W., Akolekar R., Zheng Y.W., Leung T.Y., Sun H., Chan K.C., et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011, 342:c7401.
43. Palomaki G.E., Kloza E.M., Lambert-Messerlian G.M., Haddow J.E., Neveux L.M., Ehrich M., et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011, 13:913-920.
44. Palomaki G.E., Deciu C., Kloza E.M., Lambert-Messerlian G.M., Haddow J.E., Neveux L.M., et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012, 14:296-305.
45. Bianchi D.W., Platt L.D., Goldberg J.D., Abuhamad A.Z., Sehnert A.J., Rava R.P. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119:890-901. MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group.
46. Norton M.E., Brar H., Weiss J., Karimi A., Laurent L.C., Caughey A.B., et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012, 207:137. e1-8.
47. Cicero S., Bindra R., Rembouskos G., Spencer K., Nicolaides K.H. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 2003, 23:306-310.